Evan Stein Articles

Events are the driver in PCSK9 cardiovascular outcomes trials

A recurrent question at ACC.2017 was why FOURIER had a short duration of follow-up, given the average duration of the statin trials was typically in the region of 4-5 years. This debate has been fanned by colourful but misinformed reports in the investment media (1).’…

Prof Evan Stein: What are the key messages from FOURIER?

PCSK9 inhibition: a role in treating sepsis?

Microbial cell walls contain pathogen lipids, such as lipopolysaccharide, which not only act as ligands for innate immune receptors, but also trigger the inflammatory response during sepsis (1). These pathogen lipids are mainly cleared by hepatic uptake, a process which also involves the low-density lipoprotein…

PCSK9 monoclonal antibody therapy: pharmacodynamics, efficacy and safety

Webcast Prof Evan Stein, University of Cincinnati Medical Center, Cincinnati, Ohio, USA overviews the clinical development of PCSK9 monoclonal antibody therapy Report from State-of-the-Art PCSK9 Science: Current understanding and therapeutic perspectives Prof Evan Stein discusses the pharmacodynamics of the two most advanced PCSK9 monoclonal antibody…

What are the gaps in knowledge about the PCSK9 inhibitors

Large clinical studies of innovative monoclonal antibodies targeting PCSK9 to significantly reduce low density lipoprotein cholesterol (LDL-C). Professor Evan Stein predicts the therapies will be on the market in 2015.

Take home messages from ACC2014

Results of studies presented in 2014, show that PCSK9 inhibitors: 1) very effectively reduce low density lipoprotein cholesterol (LDL-C); and 2) show consistently predictable safety profiles. The positive results of short-term studies are now being reported in longer terms and larger clinical studies, Dr Evan…

Lowering LDL-C: How low and for how long?

Treatment to reduce low density lipoprotein cholesterol (LDL-C) should be started in teenage years in people with very high risk of cardiovascular death or events e.g. heart attacks. There is substantial evidence showing significant benefits if LDL-C is reduced by about 50%, Professor Evan Stein…

What are the gaps in knowledge about the PCSK9 inhibitors

Take home messages from ACC2014

Results of studies presented in 2014, show that PCSK9 inhibitors: 1) very effectively reduce low density lipoprotein cholesterol (LDL-C); and 2) show consistently predictable safety profiles. The positive results of short-term studies are now being reported in longer terms and larger clinical studies, Dr Evan…

In your opinion, what are the optimum patient populations for PCSK9 monoclonal antibody therapy?

PCSK9 monoclonal antibodies offer very important new treatments to lowed low density lipoprotein cholesterol (LDL-C) in patients who cannot tolerate statins or whose LDL-C is inadequately reduced as well as those people with high LDL-C caused by Familial Hypercholesterolemia.